Your session is about to expire
← Back to Search
Nivolumab + Relatlimab for Melanoma (RELATIVITY-098 Trial)
RELATIVITY-098 Trial Summary
This trial will compare nivolumab + relatlimab to nivolumab alone to see if the combo is more effective in treating melanoma.
RELATIVITY-098 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRELATIVITY-098 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RELATIVITY-098 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am a teenager and can do most activities without help.I have had myocarditis in the past.I can provide a sample of my tumor for testing.I do not have any serious or uncontrolled medical conditions.I have an autoimmune disease.I have had a COVID-19 infection within the last 4 weeks.I am 18 or older and can do all my own self-care.I have never received immunotherapy for any cancer.I've been confirmed disease-free by a recent physical exam and imaging.I was diagnosed with Stage IIIA/B/C/D or IV melanoma and had surgery to remove it completely.I had surgery to remove my tumor completely within the last 3 months.I have had eye melanoma in the past.I have brain or spinal cord metastases that haven't been treated or removed.
- Group 1: Arm A: Nivolumab Plus Relatlimab
- Group 2: Arm B: Nivolumab
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many study participants are there in total?
"The sponsor, Bristol-Myers Squibb, needs to enroll 1050 patients that meet the clinical trial's inclusion criteria . The study will take place at University Of Colorado in Atlanta, Georgia and Emory University Hospital in Aurora, Colorado."
Are new patients being accepted into this research project?
"That is correct. The information provided on clinicaltrials.gov indicates that the trial is looking for 1050 individuals at 88 sites."
How does the Nivolumab + Relatlimab Fixed Dose Combination affect patients long-term?
"Nivolumab + Relatlimab Fixed Dose Combination is estimated to be a 3 on Power's 1-3 scale."
Why is Nivolumab + Relatlimab Fixed Dose Combination commonly prescribed?
"Nivolumab + Relatlimab Fixed Dose Combination is most commonly used as a treatment for malignant neoplasms; however, it can also be effective in treating metastatic esophageal adenocarcinoma, squamous cell carcinoma, and unresectable melanoma."
Has this sort of treatment been done before?
"Nivolumab + Relatlimab Fixed Dose Combination has undergone clinical study since 2010. Medarex first sponsored a 127-person Phase 1 trial in 2010, which ultimately led to the drug's approval. In the present day, there are 749 active trials for Nivolumab + Relatlimab Fixed Dose Combination being conducted across 2348 cities and 50 countries."
At how many different geographical locations is this trial being conducted?
"Across 88 different enrolment locations, this trial currently has University Of Colorado in Atlanta, Emory University Hospital in Aurora, and Sacred Heart Medical Group in Pensacola as participants."
Are there other instances where Nivolumab and Relatlimab have been studied together?
"The Nivolumab + Relatlimab Fixed Dose Combination was first examined in 2010 at the H. Lee Moffitt Cancer Center and Research Institute. There have been 249 completed trials since then, with 749 more ongoing as of now. Many of these are based out of Atlanta, Georgia."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger